MRC1 and central nervous system cancer: Although 8/9 hypermutated gliomas in McCord et al. [8] had MMR immunohistochemical loss and MMR mutations, MSI status was not explored and whether hypermutated gliomas identified by means of MMR immunohistochemical loss are responsive to immune check point inhibitors remained unsolved.